Payment overview · 2025
General Payments
$346.17
17 reported records · 9 companies
Healthcare provider profile · identity verified
Joseph C Colucci, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MASSAPEQUA, NY · NPI 1770506164
Verified facts
What the public records show
CMS Open Payments records show Joseph C Colucci, M.D. received $346.17 in general payments during 2025 across 17 reported records.
Merck Sharp & Dohme LLC accounted for 36.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Jardiance, Wegovy.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Wegovy by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $127.12 | 36.7% | 7 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $54.32 | 15.7% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $38.12 | 11.0% | 2 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $29.20 | 8.4% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $21.80 | 6.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.84 | 6.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.74 | 6.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $19.64 | 5.7% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $14.39 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $346.17 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $127.12 | 7 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $54.32 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $38.12 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $21.80 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.84 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.74 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $19.64 | 1 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $14.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 34 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | 11 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
105 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 580 | 179 |
| Levothyroxine Sodium | Levothyroxine Sodium | 463 | 118 |
| Amlodipine Besylate | Amlodipine Besylate | 435 | 128 |
| Alprazolam | Alprazolam | 347 | 87 |
| Metoprolol Succinate | Metoprolol Succinate | 295 | 96 |
| Omeprazole | Omeprazole | 271 | 81 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 231 | 79 |
| Simvastatin | Simvastatin | 226 | 61 |
| Losartan Potassium | Losartan Potassium | 217 | 64 |
| Ezetimibe | Ezetimibe | 215 | 64 |
| Metformin Hcl | Metformin Hcl | 209 | 62 |
| Zolpidem Tartrate | Zolpidem Tartrate | 189 | 32 |
| Sertraline Hcl | Sertraline Hcl | 173 | 48 |
| Furosemide | Furosemide | 165 | 52 |
| Famotidine | Famotidine | 155 | 56 |
| Clonazepam | Clonazepam | 150 | 45 |
| Celecoxib | Celecoxib | 145 | 46 |
| Glimepiride | Glimepiride | 145 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 142 | 44 |
| Gabapentin | Gabapentin | 141 | 45 |
| Allopurinol | Allopurinol | 129 | 37 |
| Synthroid | Levothyroxine Sodium | 125 | 27 |
| Metformin Hcl Er | Metformin Hcl | 109 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 105 | 44 |
| Ozempic | Semaglutide | 105 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 104 | 33 |
| Valsartan | Valsartan | 104 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 101 | 27 |
| Enalapril Maleate | Enalapril Maleate | 96 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 96 | 26 |
| Potassium Chloride | Potassium Chloride | 96 | 28 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 94 | 27 |
| Farxiga | Dapagliflozin Propanediol | 92 | 23 |
| Januvia | Sitagliptin Phosphate | 85 | 26 |
| Lisinopril | Lisinopril | 84 | 23 |
| Prednisone | Prednisone | 82 | 49 |
| Hydralazine Hcl | Hydralazine Hcl | 80 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 79 | 21 |
| Meclizine Hcl | Meclizine Hcl | 77 | 27 |
| Carvedilol | Carvedilol | 70 | 22 |
| Diazepam | Diazepam | 69 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 67 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 64 | 18 |
| Eliquis | Apixaban | 63 | 15 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 63 | 16 |
| Atenolol | Atenolol | 62 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 60 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 58 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 57 | 17 |
| Ibandronate Sodium | Ibandronate Sodium | 56 | 18 |
| Tramadol Hcl | Tramadol Hcl | 56 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 15 |
| Meloxicam | Meloxicam | 54 | 17 |
| Bupropion Xl | Bupropion Hcl | 52 | 14 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 52 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 45 | 19 |
| Montelukast Sodium | Montelukast Sodium | 41 | 14 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 41 | 13 |
| Donepezil Hcl | Donepezil Hcl | 34 | 12 |
| Fenofibrate | Fenofibrate | 34 | suppressed |
| Jardiance | Empagliflozin | 34 | 11 |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 33 | 12 |
| Trulicity | Dulaglutide | 33 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 32 | 11 |
| Finasteride | Finasteride | 31 | 11 |
| Gemfibrozil | Gemfibrozil | 31 | suppressed |
| Linzess | Linaclotide | 31 | suppressed |
| Lorazepam | Lorazepam | 30 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Testosterone | Testosterone | 29 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | 19 |
| Lovastatin | Lovastatin | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 27 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 23 |
| Ondansetron Odt | Ondansetron | 26 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 26 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 25 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 24 | suppressed |
| Triazolam | Triazolam | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Livalo | Pitavastatin Calcium | 23 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 22 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 22 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 21 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 16 |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Methimazole | Methimazole | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 14 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Ssd | Silver Sulfadiazine | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Gemtesa | Vibegron | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 13 |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 13 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Wegovy | Semaglutide | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | 12 |
| Dutasteride | Dutasteride | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Halcion | Triazolam | 11 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 11 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Xanax | Alprazolam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $346.17 · 17 records | Merck Sharp & Dohme LLC | GEMTESA, GLASSIA, JARDIANCE, LEQVIO, TZIELD, VERQUVO, WATCHMAN FLX, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error